October 05, 2006 23:59 ET

OPMEDIC GROUP, Warnex Announce settlement

(TSX: "OMG"), a healthcare-related services company providing facilities and
services to patients and surgeons, and Warnex Inc. (TSX: WNX) ("Warnex"), a
biotechnology company providing advanced diagnostic products and science-based
services, today announced a settlement of the dispute between the two
companies regarding the collection of blood samples for the purpose of
prenatal screening.

The settlement resolves all outstanding issues between the two companies
regarding Warnex's contract with OPMEDIC GROUP. To resolve the matter, OPMEDIC
GROUP has agreed to pay Warnex a total of $1,250,000, half of which will be
paid now and the other half in October 2007. From now on, OPMEDIC GROUP may
offer any prenatal screening test without any restriction regarding blood
sample collection.

"We are happy to resolve this dispute, said Mark Busgang, President and
Chief Executive Officer, Warnex. These past months of discussion with OPMEDIC
GROUP have concluded with a satisfactory agreement for both parties."

"We are pleased to reach this amicable settlement and resolve the issues
between the two companies, said Dr Pierre St-Michel, Chairman of the Board,
OPMEDIC GROUP. We look forward to getting back to the normal run of business
and remain focused on our business plan."

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk and volatility of share price, and other important factors that
could cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the second
quarter ended June 30, 2006, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.


OPMEDIC GROUP is a company incorporated under the laws of the Province of
Quebec which provides healthcare-related services including surgical
facilities and services to patients and surgeons (with its OPMEDIC division),
fertility treatments, medical imaging, laboratory services and diagnostic
procedures (with its PROCREA Cliniques division) and sperm banking services
(with its PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common
Shares trade on the Toronto Stock Exchange under the symbol "OMG".

This news release does not constitute an offer to sell or to solicitation
of an offer to buy any security and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offering would be
unlawful. This news release contains certain forward-looking statements that
reflect the current views and/or expectations of OPMEDIC GROUP with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
vary significantly.

The Content of this press release has not been approved by nor submitted
to the TSX which assumes no liability therefore.

Contact Information